Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.

Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.

PMID:
29754820
2.

Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy.

Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH.

Nat Rev Cancer. 2018 May 4. doi: 10.1038/s41568-018-0019-2. [Epub ahead of print]

PMID:
29728690
3.

Oncolytic viruses as engineering platforms for combination immunotherapy.

Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH.

Nat Rev Cancer. 2018 Jul;18(7):419-432. doi: 10.1038/s41568-018-0009-4. Review. Erratum in: Nat Rev Cancer. 2018 May 4;:.

PMID:
29695749
4.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.

BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.

5.

A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer.

Martin SD, Wick DA, Nielsen JS, Little N, Holt RA, Nelson BH.

Oncoimmunology. 2017 Sep 21;7(1):e1371895. doi: 10.1080/2162402X.2017.1371895. eCollection 2017.

6.

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, Gao B, Gebski V, Garès V, Christie EL, Wouters MCA, Milne K, George J, Patch AM, Li J, Arnau GM, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond SM, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, McNally O, Mileshkin L, Hamilton A, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale P, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P, Nelson BH, Bowtell DDL, deFazio A; Nadia Traficante, for the Australian Ovarian Cancer Study Group.

Clin Cancer Res. 2018 Feb 1;24(3):569-580. doi: 10.1158/1078-0432.CCR-17-1621. Epub 2017 Oct 23.

PMID:
29061645
7.

PD-L1 and intratumoral immune response in breast cancer.

Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH.

Oncotarget. 2017 May 30;8(31):51641-51651. doi: 10.18632/oncotarget.18305. eCollection 2017 Aug 1.

8.

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.

Tessier-Cloutier B, Kalloger SE, Al-Kandari M, Milne K, Gao D, Nelson BH, Renouf DJ, Sheffield BS, Schaeffer DF.

BMC Cancer. 2017 Sep 5;17(1):618. doi: 10.1186/s12885-017-3634-5.

9.

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.

Nielsen JS, Chang AR, Wick DA, Sedgwick CG, Zong Z, Mungall AJ, Martin SD, Kinloch NN, Ott-Langer S, Brumme ZL, Treon SP, Connors JM, Gascoyne RD, Webb JR, Berry BR, Morin RD, Macpherson N, Nelson BH.

Oncoimmunology. 2017 Apr 28;6(7):e1321184. doi: 10.1080/2162402X.2017.1321184. eCollection 2017.

10.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

PMID:
28777143
11.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

PMID:
28777142
12.

Immunotherapy for gynecological cancers: opportunities abound.

Nelson BH, Jazaeri AA.

Gynecol Oncol. 2017 Jun;145(3):411-412. doi: 10.1016/j.ygyno.2017.05.003. No abstract available.

PMID:
28552394
13.

Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.

Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, Rahimi K, Shaw PA, Clarke BA, Nelson BH.

Clin Cancer Res. 2017 Feb 15;23(4):925-934. doi: 10.1158/1078-0432.CCR-16-1433. Epub 2016 Sep 6.

14.

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.

Sheffield BS, Fulton R, Kalloger SE, Milne K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E, Laskin J, Jones SJ, Marra MA, Yip S, Nelson BH, Gown AM, Ho C, Ionescu DN.

J Histochem Cytochem. 2016 Oct;64(10):587-600. doi: 10.1369/0022155416665338. Epub 2016 Sep 2.

15.

Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.

Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, Mann KK, Assouline S, Johnson NA, Morin RD.

Clin Chem. 2016 Sep;62(9):1238-47. doi: 10.1373/clinchem.2016.255315. Epub 2016 Jul 20.

16.

CD103 and Intratumoral Immune Response in Breast Cancer.

Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH.

Clin Cancer Res. 2016 Dec 15;22(24):6290-6297. Epub 2016 Jun 7.

17.

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.

Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH.

PLoS One. 2016 May 18;11(5):e0155189. doi: 10.1371/journal.pone.0155189. eCollection 2016.

18.

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

Webb JR, Milne K, Kroeger DR, Nelson BH.

Gynecol Oncol. 2016 May;141(2):293-302. doi: 10.1016/j.ygyno.2016.03.008. Epub 2016 Mar 16.

PMID:
26972336
19.

Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.

Kroeger DR, Milne K, Nelson BH.

Clin Cancer Res. 2016 Jun 15;22(12):3005-15. doi: 10.1158/1078-0432.CCR-15-2762. Epub 2016 Jan 13.

20.

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells.

Nielsen JS, Sedgwick CG, Shahid A, Zong Z, Brumme ZL, Yu S, Liu L, Kroeger DR, Treon SP, Connors JM, Gascoyne RD, Berry BR, Marra MA, Morin RD, Macpherson N, Nelson BH.

Clin Cancer Res. 2016 May 1;22(9):2226-36. doi: 10.1158/1078-0432.CCR-15-2023. Epub 2015 Dec 2.

21.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

22.

Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.

Martin SD, Coukos G, Holt RA, Nelson BH.

Ann Oncol. 2015 Dec;26(12):2367-74. doi: 10.1093/annonc/mdv382. Epub 2015 Sep 14. Review.

23.

The more tumors change, the more they stay tame: do T cells keep POLE ultramutated endometrial carcinomas in check?

Nelson BH, McAlpine JN.

Gynecol Oncol. 2015 Jul;138(1):1-2. doi: 10.1016/j.ygyno.2015.06.004. No abstract available.

PMID:
26072691
24.

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.

Webb JR, Milne K, Nelson BH.

Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.

25.

Recurrent genomic rearrangements in primary testicular lymphoma.

Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, Steidl C.

J Pathol. 2015 Jun;236(2):136-41. doi: 10.1002/path.4522. Epub 2015 Mar 26.

PMID:
25712539
26.

New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer.

Nelson BH.

Curr Opin Immunol. 2015 Apr;33:93-100. doi: 10.1016/j.coi.2015.02.004. Epub 2015 Feb 21. Review.

PMID:
25710852
27.

CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.

deLeeuw RJ, Kroeger DR, Kost SE, Chang PP, Webb JR, Nelson BH.

Cancer Immunol Res. 2015 Mar;3(3):245-53. doi: 10.1158/2326-6066.CIR-14-0146. Epub 2014 Dec 5.

28.

Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy.

Johnson LD, Nesslinger NJ, Blood PA, Chima N, Richier LR, Ludgate C, Pai HH, Lim JT, Nelson BH, Vlachaki MT, Lum JJ.

Oncoimmunology. 2014 Jun 25;3:e29243. eCollection 2014.

29.
30.

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.

Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA.

Genome Res. 2014 May;24(5):743-50. doi: 10.1101/gr.165985.113. Epub 2014 Apr 29.

31.

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, Nelson BH.

Clin Cancer Res. 2014 Mar 1;20(5):1125-34. doi: 10.1158/1078-0432.CCR-13-2147. Epub 2013 Dec 9.

32.

Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.

Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH.

Clin Cancer Res. 2014 Jan 15;20(2):434-44. doi: 10.1158/1078-0432.CCR-13-1877. Epub 2013 Nov 4.

33.

Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells.

Sio A, Chehal MK, Tsai K, Fan X, Roberts ME, Nelson BH, Grembecka J, Cierpicki T, Krebs DL, Harder KW.

Cancer Res. 2013 Oct 1;73(19):5892-904. doi: 10.1158/0008-5472.CAN-13-0842. Epub 2013 Aug 1.

34.

Tumor-infiltrating B cells and T cells: Working together to promote patient survival.

Nielsen JS, Nelson BH.

Oncoimmunology. 2012 Dec 1;1(9):1623-1625.

35.

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer.

West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH.

Br J Cancer. 2013 Jan 15;108(1):155-62. doi: 10.1038/bjc.2012.524. Epub 2012 Nov 20.

36.

Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.

Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH, Holt RA.

J Pathol. 2013 Mar;229(4):515-24. doi: 10.1002/path.4105. Epub 2012 Nov 29.

PMID:
22996961
37.

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH.

Clin Cancer Res. 2012 Jun 15;18(12):3281-92. doi: 10.1158/1078-0432.CCR-12-0234. Epub 2012 May 2.

38.

The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature.

deLeeuw RJ, Kost SE, Kakal JA, Nelson BH.

Clin Cancer Res. 2012 Jun 1;18(11):3022-9. doi: 10.1158/1078-0432.CCR-11-3216. Epub 2012 Apr 17. Review.

39.

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes.

Milne K, Alexander C, Webb JR, Sun W, Dillon K, Kalloger SE, Gilks CB, Clarke B, Köbel M, Nelson BH.

J Transl Med. 2012 Feb 27;10:33. doi: 10.1186/1479-5876-10-33.

40.

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.

Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.

41.

Killer T cells to the rescue in ovarian cancer.

Nelson BH.

Gynecol Oncol. 2012 Feb;124(2):178-9. doi: 10.1016/j.ygyno.2011.12.434. No abstract available.

PMID:
22264602
42.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.

43.

ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.

Salzman J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, Drescher CW, Brown PO.

PLoS Biol. 2011 Sep;9(9):e1001156. doi: 10.1371/journal.pbio.1001156. Epub 2011 Sep 20.

44.

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E.

Blood. 2011 Nov 3;118(18):4853-62. doi: 10.1182/blood-2011-01-329656. Epub 2011 Sep 9.

45.

A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation.

Ho VW, Leung K, Hsu A, Luk B, Lai J, Shen SY, Minchinton AI, Waterhouse D, Bally MB, Lin W, Nelson BH, Sly LM, Krystal G.

Cancer Res. 2011 Jul 1;71(13):4484-93. doi: 10.1158/0008-5472.CAN-10-3973. Epub 2011 Jun 14.

46.

Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.

Tran E, Nielsen JS, Wick DA, Ng AV, Johnson LD, Nesslinger NJ, McMurtrie E, Webb JR, Nelson BH.

PLoS One. 2010 Dec 22;5(12):e15625. doi: 10.1371/journal.pone.0015625.

47.

Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C).

Wick DA, Martin SD, Nelson BH, Webb JR.

Vaccine. 2011 Jan 29;29(5):984-93. doi: 10.1016/j.vaccine.2010.11.036. Epub 2010 Nov 27.

PMID:
21115055
48.

CD20+ B cells: the other tumor-infiltrating lymphocytes.

Nelson BH.

J Immunol. 2010 Nov 1;185(9):4977-82. doi: 10.4049/jimmunol.1001323. Review.

49.

An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.

Nielsen JS, Wick DA, Tran E, Nelson BH, Webb JR.

J Immunol Methods. 2010 Aug 31;360(1-2):149-56. doi: 10.1016/j.jim.2010.07.003. Epub 2010 Jul 15.

PMID:
20637775
50.

A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.

Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL, Nelson BH.

Clin Cancer Res. 2010 Aug 1;16(15):4046-56. doi: 10.1158/1078-0432.CCR-10-0948. Epub 2010 Jun 18.

Supplemental Content

Loading ...
Support Center